A- A A+

Hepatitis C Testing, Care and Treatment at Harm Reduction Centres in the European Union: a 28-Country Survey of Service Providers

Prof Jeffrey V. Lazarus, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/7011/14H30_5_Jeffrey Lazarus.pptx

Direct-acting interferon-free therapies and reinfection among people who inject drugs

Jason Grebely, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/6960/11H00_2_Jason Grebely.pptx

How to eliminate HCV in people who inject drugs in the USA

Dahari, Harel et al.

The Lancet Infectious Diseases , Volume 0 , Issue 0 , Published: 15 November 2017, doi.org/10.1016/S1473-3099(17)30678-3

Abstract

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30678-3/fulltext

HCV treatment as prevention in Europe: model projections and impact of current and scaled-up treatment rates

Hannah Fraser, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/7283/12H45_5_Hannah Fraser.pptx

InXFo: Unabhängiger Service für HIV-Behandler, Hepatologen und Ärzte in der fachgebietsübergreifenden Versorgung von Patienten mit HIV- und/oder Hepatitis-Infektion

InXFo ist ein unabhängiger Service für HIV-Behandler, Hepatologen und Ärzte, die in der fachgebietsübergreifenden Versorgung von Patienten mit HIV- und/oder Hepatitis-Infektion tätig sind.
InXFo bietet Ärzten eine kostenfreie und individuelle Beantwortung von medizinischen Anfragen bezüglich Patienten mit HIV- und/oder Hepatitis-Infektion.
Das InXFo-Team, das aus Experten verschiedenster Fachbereiche besteht, beantwortet per Internet und per Email Ihre Anfragen innerhalb von drei Arbeitstagen. Bei komplexen Fragestellungen erfolgt zur Beantwortung der Anfrage ein fachübergreifender Wissensaustausch .

Was ist zu tun um den kostenfreien Service in Anspruch zu nehmen?
Melden Sie sich einmalig bei InXFo an und stellen Sie, nach Erhalt der Anmeldebestätigung, jederzeit Ihre Frage. (Unterstützt von Gilead, Abbvie, MSD, Janssen, ViiV Healthcare und TemmeKlein Rechtsanwälte, November 2017)

http://www.inxfo.de/

Access to HCV treatment under special consideration in prison

Gabriele Fischer, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/6977/14H30_3_Gabriele Fischer.pptx

The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.

Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, Stanley A, Bathgate A, McDonald SA, Goldberg D, Valerio H, Fox R, Kennedy N, Bramley P, Hutchinson SJ.

J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429-7. doi: 10.1016/j.jhep.2017.10.033.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29155019

NRW. Empfehlung der Landeskommission AIDS zur Verbesserung der Lebenssituation von Drogen gebrauchenden Menschen im Kontext von HIV/Aids und Hepatitis.

(Landeskommission AIDS, NRW, 04.05.2017)

http://www.landesstellesucht-nrw.de/tl_files/images/pages/PDFs/Empfehlung%20LK%20AIDS%20Drogengebraucher%20verabschiedet%202017-05-04.pdf

A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development

Y Boege et al.

Cancer Cell 32 (3), 342-359.e10. 2017 Sep 11.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598544/

Discover the EASL educational tools - NEW! EASL HCV Advisor

EASL online education allows you to continue learning using a variety of platforms.

http://www.easl.eu/research/training-the-liver-study/easl-educational-tools

DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.

Gaby S Steba, Sylvie M Koekkoek, Joost W Vanhommerig, Kees Brinkman, David Kwa, Jan T M Van Der Meer, Maria Prins, Ben Berkhout, Michael Tanck, William A Paxton, Richard Molenkamp, Janke Schinkel;

The Journal of Infectious Diseases, , jix587, doi.org/10.1093/infdis/jix587

https://watermark.silverchair.com/jix587.pdf

Concomitant psychiatric and non-alcohol related substance use disorders among hospitalized patients with alcoholic liver disease in the United States.

Jinjuvadia R, Jinjuvadia C, Puangsricharoen P, Chalasani N, Crabb DW, Liangpunsakul S; Translational Research Evolving Alcoholic Hepatitis Treatment Consortium.

Alcohol Clin Exp Res. 2017 Dec 2. doi: 10.1111/acer.13567.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29197092

Cost-effectiveness of Direct-acting Antivirals for Treatment of Hepatitis C Genotypes 2–6

T. He; M. A. Lopez-Olivo; C. Hur; J. Chhatwal

Aliment Pharmacol Ther. 2017;46(8):711-721. 

https://www.medscape.com/viewarticle/887693

The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.

Li DK, Ren Y, Fierer DS, Rutledge S, Shaikh OS, Lo Re V 3rd, Simon T, Abou-Samra AB, Chung RT, Butt AA.

Hepatology. 2017 Dec 2. doi: 10.1002/hep.29707.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29205416

Hepatitis C: Noch mehr Infizierte behandeln

Dtsch Arztebl 2017; 114(40): A-1803 / B-1535 / C-1506

Lenzen-Schulte, Martina

Nur ein Bruchteil aller Hepatitis-C-Infizierten erhält eine Therapie mit modernen Antiviralia. Viele Experten sind von deren Nutzen überzeugt, obwohl ein Cochrane Review dies in Zweifel zog. Offenbar ist eine Virusclearance doch ein gutes Zeichen.

https://www.aerzteblatt.de/archiv/193784/Hepatitis-C-Noch-mehr-Infizierte-behandeln

Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK

Williams, Roger et al.

The Lancet , Volume 0 , Issue 0 , Published online: November 29, 2017
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32866-0/fulltext

The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong.

Kwo PY, Shiffman ML, Bernstein DE.

Am J Gastroenterol. 2017 Nov 14. doi: 10.1038/ajg.2017.420.

https://www.nature.com/articles/ajg2017420

WHO guidelines on testing for hepatitis B and C – meeting targets for testing

Margaret E. HellardDiese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein!Roger Chou and Philippa Easterbrook

BMC Infectious DiseasesBMC series – open, inclusive and trusted

2017,17(Suppl 1):703

doi.org/10.1186/s12879-017-2765-2, ©  World Health Organization. 2017

Published: 1 November 2017

https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2765-2

Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.

Buggisch P, Vermehren J, Mauss S, Günther R, Schott E, Pathil A, Boeker K, Zimmermann T, Teuber G, Vornkahl HP, Simon KG, Niederau C, Wedemeyer H, Zeuzem S.

J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32431-5. doi: 10.1016/j.jhep.2017.11.009.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29133244

Testing for chronic hepatitis B and C – a global perspective

Research

Publication of this supplement was funded by the WHO. Information about the source of funding for specific projects can be found in the individual articles. The articles have undergone the journal's standard peer review process for supplements.

Edited by Philippa Easterbrook, Roger Chou, Margaret Hellard and Philippa Harris
BMC Infectious Diseases, Volume 17 Supplement 1
https://bmcinfectdis.biomedcentral.com/articles/supplements/volume-17-supplement-1?sap-outbound-id=9A23640CA625A6815A56AC7EC44778D9C318D77E

HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985-2015.

van Santen DK, van der Helm JJ, Lindenburg K, Schim van der Loeff M, Prins M.

Int J Drug Policy. 2017 Sep;47:95-101. doi: 10.1016/j.drugpo.2017.05.026.

http://www.ijdp.org/article/S0955-3959(17)30130-5/fulltext

The IDUIT Brief Guide for People who Use Drugs

People who use drugs are heavily affected by HIV, hepatitis C (HCV), and tuberculosis (TB) and are often neglected in countries’ and cities’ responses to the epidemics. There are effective means to prevent and treat HIV, HCV and TB among people who use drugs, but resources (financial, human and material) are often not adequately invested to make them accessible. The reasons for this are multifaceted and include criminalization, stigma, discrimination and denial of basic human rights to people who use drugs. This IDUIT Brief Guide for People who Use Drugs is intended to outline the key concepts of Implementing Comprehensive HIV and HCV Programs with People who Inject Drugs: Practical Guidance for Collaborative Interventions (the IDUIT) related to prevention, treatment and empowerment with regard to HIV and HCV, and point to how activists and professionals from among the community of people who use drugs might promote better policy and practice. (INPUD - International Network of People Who Use Drugs, 2017)

http://fileserver.idpc.net/library/The-IDUIT-Brief-Guide-for-PUDs-Online.pdf

Hepatitis C and Human Immunodeficiency Virus Co-Infection in the Era of Direct-Acting Antiviral Agents: No Longer A Difficult to Treat Population.

Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S.

Hepatology. 2017 Nov 6. doi: 10.1002/hep.29642.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29108121

WORLD HEPATITIS SUMMIT: NO ELIMINATION WITHOUT DECRIMINALIZATION! 18 civil society organisations call world leaders to promote harm reduction and decriminalise drug use

São Paulo, Brazil. At the occasion of the World Hepatitis Summit, a large coalition of patients, clinicians, social workers, representatives of the drug using community, researchers, and public health experts express their whole-hearted support to the commitment of the World Health Organization (WHO)’s goal to eliminate viral hepatitis by 2030; and declare that this goal will only be achieved if people who use drugs have access to effective, affordable prevention and treatment programs. (hep C coalistion, 02.11.2017)

http://www.hepcoalition.org/advocate/campaigns/article/world-hepatitis-summit-no-elimination-without-decriminalization

Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.

Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK.

Curr Opin Infect Dis. 2015 Dec;28(6):576-82. doi: 10.1097/QCO.0000000000000216.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659818/

Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study

Zelenev, Alexei et al.

The Lancet Infectious Diseases , Volume 0 , Issue 0 , Published: 15 November 2017, doi.org/10.1016/S1473-3099(17)30676-X

Abstract

http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30676-X/fulltext